Transgene SA - Product Size & Share - 2015 - PowerPoint PPT Presentation

Loading...

PPT – Transgene SA - Product Size & Share - 2015 PowerPoint presentation | free to download - id: 7f2421-NTY2M



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Transgene SA - Product Size & Share - 2015

Description:

This report provides comprehensive information on the current therapeutic developmental pipeline of Transgene SA s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Enquiry @ – PowerPoint PPT presentation

Number of Views:4

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Transgene SA - Product Size & Share - 2015


1
Transgene SA - Product Pipeline Review - 2015
Published on October - 2015
2
.
Report Overview
About Transgene SA - Product Pipeline Review -
2015 Research Beam added report on Transgene SA
Product Pipeline Review - 2015. Summary Global
Markets Directs, Transgene SA Product Pipeline
Review - 2015, provides an overview of the
Transgene SA s Transgene SA research and
development focus. This report provides
comprehensive information on the current
therapeutic developmental pipeline of Transgene
SA s, complete with comparative analysis at
various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of
administration (RoA) and molecule type. It also
reviews latest updates, and featured news and
press releases, along with special features on
late-stage and discontinued projects. Get Full
Details On http//www.researchbeam.com/transgene
-sa-product-pipeline-review-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.
4
.
Report Overview
Scope The report provides brief overview of
Transgene SA including business description, key
information and facts, and its locations and
subsidiaries The report reviews current pipeline
of Transgene SA s human therapeutic division and
enlists all their major and minor projects The
report features product description and
descriptive mechanism of action for key pipeline
products along with the products developmental
history and major milestones Special feature on
out-licensed and partnered product portfolio The
report summarizes all the dormant and
discontinued pipeline projects Latest company
statement Latest news and deals relating to the
Transgene SA s pipeline products  
5
Report Overview
  • Reasons to buy
  •  Evaluate Transgene SA s strategic position with
    total access to detailed information on its
    product pipeline
  • Assess the growth potential of Transgene SA in
    its therapy areas of focus
  • Identify new drug targets and therapeutic classes
    in the Transgene SA s RD portfolio and develop
    key strategic initiatives to reinforce pipeline
    in those areas
  • Exploit in-licensing opportunities by identifying
    windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding
    the focus areas of Transgene SA and exploit
    collaboration and partnership opportunities
  • Identify emerging players with potentially strong
    product portfolio and create effective
    counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by
    identifying the most promising pipeline of
    Transgene SA
  • Develop and design in-licensing and out-licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope
  • Explore the dormant and discontinued projects of
    Transgene SA and identify potential
    opportunities in those areas

6
Table Of Contents
Table of Contents 2 List of Tables 6 List of
Figures 6 Transgene SA Snapshot 7 Transgene SA
Overview 7 Key Information 7 Key Facts
7 Transgene SA - Research and Development
Overview 8 Key Therapeutic Areas 8 Transgene SA
- Pipeline Review 11 Pipeline Products by Stage
of Development 11 Pipeline Products - Monotherapy
12 Pipeline Products - Combination Treatment
Modalities 13 Pipeline Products - Partnered
Products 14
7
Table Of Contents
Partnered Products/Combination Treatment
Modalities 15 Pipeline Products - Out-Licensed
Products 16 Out-Licensed Products/Combination
Treatment Modalities 17 Transgene SA - Pipeline
Products Glance 18 Transgene SA - Late Stage
Pipeline Products 18 Partnered Products/Combinatio
n Treatment Modalities 15 Pipeline Products -
Out-Licensed Products 16 Out-Licensed
Products/Combination Treatment Modalities
17 Transgene SA - Pipeline Products Glance
18 Transgene SA - Late Stage Pipeline Products
18
8
Table Of Contents
Pre-Registration Products/Combination Treatment
Modalities 18 Filing rejected/Withdrawn
Products/Combination Treatment Modalities
19 Phase III Products/Combination Treatment
Modalities 20 Transgene SA - Clinical Stage
Pipeline Products 21 Phase II Products/Combination
Treatment Modalities 21 Phase I
Products/Combination Treatment Modalities
22 Transgene SA - Early Stage Pipeline Products
23 Preclinical Products/Combination Treatment
Modalities 23 Discovery Products/Combination
Treatment Modalities 24 Enquiry about this
report _at_ http//www.researchbeam.com/transgene-sa-
product-pipeline-review-2015-market/enquire-about-
report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/transgene-sa-product-p
ipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com